Aim Immunotech Share Price (NYSE: AIM)

$0.54

▲

-0.05

(-8.47%)

Last updated on April 8, 2026 at 1:20 am IST

$₹

Check the interactive Aim Immunotech Stock chart to analyse performance

Aim Immunotech stock performance

as on April 8, 2026 at 1:20 am IST

Today's Low:$0.53
Today's High:$0.55
$0.54
1.83%
Downside
Day's Volatility :3.62%
Upside
1.82%
52 Weeks Low:$0.53
52 Weeks High:$20.33
$0.54
1.85%
Downside
52 Weeks Volatility :97.39%
Upside
97.34%

Aim Immunotech Stock Returns

Period	Aim Immunotech Inc	Index (Russel 2000)
3 Months	-57.59%	0.0%
6 Months	-77.03%	0.0%
1 Year	-94.61%	0.0%
3 Years	44.24%	0.8%

Aim Immunotech Inc Key Stats

Check Aim Immunotech key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.59
Open	$0.579
Today's High	$0.55
Today's Low	$0.5301
Market Capitalization	$4.8M
Today's Volume	$123.5K
52 Week High	$20.3297
52 Week Low	$0.53
Revenue TTM	$88.0K
EBITDA	$-11.5M
Earnings Per Share (EPS)	$-8.62
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-3138.91%

Stock Returns calculator for Aim Immunotech Stock including INR - Dollar returns

The Aim Immunotech stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Aim Immunotech investment value today

Current value as on today

Returns

(0%)

Returns from Aim Immunotech Stock

(0%)

Dollar Impact

(0%)

Indian investors sentiment towards Aim Immunotech Stock

337.84%

Period: Mar 8, 2026 to Apr 7, 2026. Change in 30 Days versus previous period

Investment in Aim Immunotech Shares from India has grown by 337.84% over the past 30 days, indicating increased transactional activity.

38%

Period: Mar 8, 2026 to Apr 7, 2026. Change in 30 Days versus previous period

Search interest for Aim Immunotech Stock from India on INDmoney has increased by 38% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Aim Immunotech Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Aim Immunotech(by analysts ranked 0 to 5 stars)

Aim Immunotech Share Price Target

What analysts predicted

Upside of 3970.0%

Target:

$21.98

Current:

$0.54

Aim Immunotech share price target is $21.98, a slight Upside of 3970.0% compared to current price of $0.54 as per analysts' prediction.

Aim Immunotech Stock Insights

Price Movement
In the last 7 days, AIM stock has moved up by 7.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 26.0K → 21.0K (in $), with an average decrease of 19.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -2.79M → -4.17M (in $), with an average decrease of 22.3% per quarter
AIM vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 56.6% return, outperforming this stock by 17.9%

Aim Immunotech Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY22

FY23

FY24

FY25

	FY22	Y/Y Change
Revenue	$141.0K	↑ 4.44%
Net Income	$-19.4M	↓ 9.61%
Net Profit Margin	-13.8K%	↑ 2144.78%

	FY23	Y/Y Change
Revenue	$202.0K	↑ 43.26%
Net Income	$-29.0M	↑ 37.35%
Net Profit Margin	-14.3K%	↑ 616.99%

	FY23	Y/Y Change
Revenue	$202.0K	↑ 43.26%
Net Income	$-29.0M	↑ 37.35%
Net Profit Margin	-14.3K%	↑ 616.99%

	FY24	Y/Y Change
Revenue	$170.0K	↓ 15.84%
Net Income	$-17.3M	↓ 40.2%
Net Profit Margin	-10.2K%	↑ 4149.38%

	FY24	Y/Y Change
Revenue	$170.0K	↓ 15.84%
Net Income	$-17.3M	↓ 40.2%
Net Profit Margin	-10.2K%	↑ 4149.38%

	FY25	Y/Y Change
Revenue	$88.0K	↓ 48.24%
Net Income	$-14.0M	↓ 19.41%
Net Profit Margin	-15.9K%	↓ 5673.12%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Revenue	$35.0K	↓ 30.0%
Net Income	$-3.7M	↑ 101.53%
Net Profit Margin	-10.6K%	↓ 6899.43%

	Q4 FY24	Q/Q Change
Revenue	$45.0K	↑ 28.57%
Net Income	$-6.0M	↑ 61.27%
Net Profit Margin	-13.3K%	↓ 2688.57%

	Q1 FY25	Q/Q Change
Revenue	$16.0K	↓ 64.44%
Net Income	$-3.7M	↓ 37.91%
Net Profit Margin	-23.2K%	↓ 9896.25%

	Q2 FY25	Q/Q Change
Revenue	$25.0K	↑ 56.25%
Net Income	$-2.8M	↓ 24.59%
Net Profit Margin	-11.2K%	↑ 11980.25%

	Q3 FY25	Q/Q Change
Revenue	$26.0K	↑ 4.0%
Net Income	$-3.3M	↑ 17.54%
Net Profit Margin	-12.6K%	↓ 1454.77%

	Q4 FY25	Q/Q Change
Revenue	$21.0K	↓ 19.23%
Net Income	$-4.2M	↑ 27.13%
Net Profit Margin	-19.9K%	↓ 7250.18%

FY22

FY23

FY24

FY25

	FY22	Y/Y Change
Profit	$565.0K	-

	FY23	Y/Y Change
Profit	$160.0K	-

	FY24	Y/Y Change
Profit	$139.0K	-

	FY25	Y/Y Change
Profit	$-250.0K	↓ 279.86%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Profit	$27.0K	↓ 35.71%

	Q4 FY24	Q/Q Change
Profit	$96.0K	↑ 255.56%

	Q1 FY25	Q/Q Change
Profit	$6.0K	↓ 93.75%

	Q2 FY25	Q/Q Change
Profit	$15.0K	↑ 150.0%

	Q3 FY25	Q/Q Change
Profit	$-96.0K	↓ 740.0%

	Q4 FY25	Q/Q Change
Profit	$-62.0K	↓ 35.42%

FY22

FY23

FY24

FY25

	FY22	Y/Y Change
Operating Cash Flow	$-16.1M	↑ 15.35%
Investing Cash Flow	$11.0M	↓ 1841.36%
Financing Cash Flow	$80.0K	↓ 99.02%

	FY23	Y/Y Change
Operating Cash Flow	$-21.3M	↑ 32.03%
Investing Cash Flow	$-832.0K	↓ 107.57%
Financing Cash Flow	$485.0K	↑ 506.25%

	FY23	Y/Y Change
Operating Cash Flow	$-21.3M	↑ 32.03%
Investing Cash Flow	$-832.0K	↓ 107.57%
Financing Cash Flow	$485.0K	↑ 506.25%

	FY24	Y/Y Change
Operating Cash Flow	$-14.9M	↓ 29.99%
Investing Cash Flow	$4.7M	-
Financing Cash Flow	$6.4M	↑ 1228.66%

	FY25	Y/Y Change
Operating Cash Flow	$-11.0M	↓ 26.4%
Investing Cash Flow	$1.9M	↓ 60.62%
Financing Cash Flow	$10.4M	↑ 61.2%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-3.1M	↑ 3.39%
Investing Cash Flow	$334.0K	↓ 59.56%
Financing Cash Flow	$137.0K	↓ 94.39%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-4.0M	↑ 27.17%
Investing Cash Flow	$3.7M	↑ 1008.98%
Financing Cash Flow	$1.0M	↑ 656.93%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-2.4M	↓ 40.3%
Investing Cash Flow	$898.0K	↓ 75.76%
Financing Cash Flow	$660.0K	↓ 36.35%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-1.5M	↓ 35.15%
Investing Cash Flow	$754.0K	↓ 16.04%
Financing Cash Flow	$355.0K	↓ 46.21%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$-5.1M	↑ 231.74%
Investing Cash Flow	$296.0K	↓ 60.74%
Financing Cash Flow	$6.7M	↑ 1774.37%

	Q4 FY25	Q/Q Change
Operating Cash Flow	$-2.0M	↓ 60.9%
Investing Cash Flow	$-95.0K	↓ 132.09%
Financing Cash Flow	$2.7M	↓ 59.14%

Aim Immunotech Technicals Summary

Sell

Neutral

Buy

Aim Immunotech is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Aim Immunotech Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aim Immunotech Inc	-24.55%	-77.03%	-94.61%	44.24%	-75.68%
Regeneron Pharmaceuticals, Inc.	-2.37%	35.32%	37.04%	-7.37%	60.58%
Beone Medicines Ltd	0.07%	-13.46%	45.08%	29.29%	-1.44%
Vertex Pharmaceuticals Incorporated	-5.77%	3.12%	-8.06%	34.36%	103.56%
Alnylam Pharmaceuticals, Inc.	2.09%	-26.7%	47.26%	60.8%	138.98%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aim Immunotech Inc	NA	NA	0.71	-4.33	-31.39	-1.01	NA	-3.19
Regeneron Pharmaceuticals, Inc.	18.38	18.38	1.62	44.88	0.15	0.06	0.0	304.65
Beone Medicines Ltd	126.85	126.85	NA	5.5	0.07	0.04	NA	39.34
Vertex Pharmaceuticals Incorporated	28.66	28.66	2.14	19.16	0.23	0.12	NA	73.49
Alnylam Pharmaceuticals, Inc.	136.85	136.85	0.64	9.25	0.73	0.07	NA	5.96

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aim Immunotech Inc	Buy	$4.8M	-75.68%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$80.5B	60.58%	18.38	31.41%
Beone Medicines Ltd	NA	$35.7B	-1.44%	126.85	5.37%
Vertex Pharmaceuticals Incorporated	Buy	$111.4B	103.56%	28.66	32.94%
Alnylam Pharmaceuticals, Inc.	Buy	$42.3B	138.98%	136.85	8.45%

About Aim Immunotech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Organization	Aim Immunotech
Employees	21
CEO	Mr. Thomas K. Equels Esq., J.D., M.S.
Industry	Health Technology

Key Management of Aim Immunotech Inc

Name	Title
Mr. Thomas K. Equels Esq., J.D., M.S.	Executive Vice Chairman, CEO & President
Mr. Peter W. Rodino III, Esq., J.D.	COO, Executive Director of Governmental Relations, General Counsel & Secretary
Ann Marie E. Coverly	Director of Administration & Human Resources and Deputy Investor Relations Coordinator
Dr. Christopher Nicodemus FACP, M.D.	Member of Scientific Advisory Board & Consulting Science Officer

Important FAQs about investing in AIM Stock from India :

What is Aim Immunotech share price today?

Aim Immunotech share price today is $0.54 as on April 8, 2026 at 1:20 am IST at the close of the market. Aim Immunotech share today touched a day high of $0.55 and a low of $0.53.

What is the 52 week high and 52 week low for Aim Immunotech share?

Aim Immunotech share touched a 52 week high of $20.33 and a 52 week low of $0.53. Aim Immunotech stock price today i.e. April 8, 2026 at 1:20 am IST is closed at $0.54, lower by 97.34% versus the 52 week high.

How to invest in Aim Immunotech Stock (AIM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aim Immunotech on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aim Immunotech Shares that will get you 2.7778 shares as per Aim Immunotech share price of $0.54 per share as on April 8, 2026 at 1:20 am IST.

What is the minimum amount required to buy Aim Immunotech Stock (AIM) from India?

Indian investors can start investing in Aim Immunotech (AIM) shares with as little as ₹92.89 or $1 (as of April 08, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹928.90 in Aim Immunotech stock (as per the Rupee-Dollar exchange rate as on April 08, 2026). Based on Aim Immunotech share’s latest price of $0.54 as on April 8, 2026 at 1:20 am IST, you will get 18.5185 shares of Aim Immunotech. Learn more about fractional shares .

What are the returns that Aim Immunotech has given to Indian investors in the last 5 years?

Aim Immunotech stock has given -75.68% share price returns and 26.4% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?